HYpharm GmbH

HYpharm was founded in 2016 with belief and mission that the rising antibiotics crisis needs innovative solutions with bacteriophage derived proteins, the so called endolysins for use in modern medicine. The emergence of bacterial strains that are resistant to many to allmost all classes of antibiotics used in human medicine is of great concern. Therefore, there is an urgent need for the development of alternatives to conventional antibiotics for the treatment and prevention of humans and food-producing animals. Bacteriophage-encoded lytic enzymes (endolysins), which degrade the cell wall of the bacterial host, are innovative alternatives to antibiotics. HYpharm offers a new antimicrobial platform technology for combating bacterial pathogens in a wide range of applications.